External Validation of the CARE-BMT and Modified CARE-BMT Scores for Cardiac Event Prediction After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia.
A refined heart disease risk tool for transplant patients now includes transplant-specific factors, improving prediction accuracy after bone marrow transplant.
This diagnostic or model validation study examined External Validation of the CARE-BMT and Modified CARE-BMT Scores for Cardiac Event Prediction After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. The PubMed abstract reports that Incorporating standard-dose PTCy improved risk stratification, supporting inclusion of transplant-specific variables in cardiovascular risk prediction after allo-HCT.
What the study was
- Study design
- Diagnostic or model validation study
- Population
- patients with acute myeloid leukemia (AML) undergoing allo-HCT
- Sample size
- 246
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Transplantation and cellular therapy
Why it surfaced
Score 6/10 reflects diagnostic or model validation study evidence with abstract only access; genuine match to Hematologic malignancies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.